Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat

doi:10.1016/0006-8993(90)91779-G

Brain Research

Volume 532, Issues 1–2, 5 November 1990, Pages 336-338

https://doi.org/10.1016/0006-8993(90)91779-G Get rights and content

Abstract

The lipid peroxidation inhibitor U74006F (21-[4-(2,6-di-1-pyrrolidinyl-4-pyyrimidinyl)-1-piperazinyl-16-methypregna-1,4,9 (11)-triene-3, 20-dione) was tested for cerebroprotective properties in the rat. Transient forebrain ischemia was induced by occlusion of the carotid arteries and simultaneous lowering of the blood pressure to 40 mmHg. Repetitive doses of 10 mg/kg U74006F were administered intraperitoneally 10 min before and again 30 min and 24 h after the transient forebrain ischemia. U74006F did not significantly improve histological outcome in this model, suggesting lipid peroxidation to be a minor determinatinant forneurological, outcome under these experimental outcome under these experimental conditions

Reference (13)

BeckT. et al.
Effects of flunarizine on postichemic blood flow, energy metabolism and cell damage in the rat brain
Eur. J. Pharmacol.
(1988)
HallE.D. et al.
Inhibition of arachidonic acid induced vasogenic brain edema by the non-glucocorticoid21-aminosteroid U74006F
Brain Research
(1988)
SauerD. et al.
Phencyclidine reduces postischemic neuronal necrosis in the rat hippocampus without changing blood flow
Neurosci. Lett.
(1988)
BielenbergG.W. et al.
Effects of emopamil in postischemic blood flow and cell damage in the rat brain
Naunyn-Schmiedeberg's Arch. Pharmacol.
(1989)
HallE.D. et al.
Attenuation of postischemic cerebral hypoperfusion by the 21-aminosteroid U74006F
Stroke
(1988)
HallE.D. et al.
21-aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils
Stroke
(1988)

There are more references available in the full text version of this article.

Cited by (48)

Pharmacologic Modification of Acute Cerebral Ischemia
2021, Stroke: Pathophysiology, Diagnosis, and Management
In this chapter we discuss the general targets for pharmacologic intervention during cerebral ischemia. Considering cerebral ischemia as a process, pharmacologic modification can be considered in four broad categories: 1) preconditioning, occurring prior to the ischemic event; 2) arterial occlusion and reperfusion of injured tissue; 3) consequences of prolonged arterial occlusion on the neurovascular unit; and 4) augmentation of the restorative processes after definitive tissue injury has occurred. In this context we will touch upon preclinical testing of cytoprotective therapies and highlight important conceptual differences in translating these findings into the clinical setting. The challenges of clinical trial design are discussed with the potential for imaging, endovascular therapy, and mobile stroke units to have a meaningful impact on the design of future clinical trials evaluating cytoprotection. Lastly, we highlight the results of clinical cytoprotective trials in historical context as well as the lessons learned to carry forward in future attempts to minimize the deleterious consequences and maximize the beneficial effects of the ischemic cascade.
Pharmacologic Modification of Acute Cerebral Ischemia
2015, Stroke: Pathophysiology, Diagnosis, and Management
Pharmacologic modification of acute cerebral ischemia
2011, Stroke: Pathophysiology, Diagnosis, and Management
Pharmacologic Modification of Acute Cerebral Ischemia
2011, Stroke
Pharmacologic Modification of Acute Cerebral Ischemia
2004, Stroke: Pathophysiology, Diagnosis, and Management
Clinical Trials For Cytoprotection In Stroke
2004, NeuroRx
To date, many cytoprotective drugs have reached the stage of pivotal phase 3 efficacy trials in acute stroke patients. (Table1) Unfortunately, throughout the neuroprotective literature, the phrase “failure to demonstrate efficacy” prevails as a common thread among the many neutral or negative trials, despite the largely encouraging results encountered in preclinical studies. The reasons for this discrepancy are multiple, and have been discussed by Dr. Zivin in his review. Many of the recent trials have addressed deficiencies of the previous ones with more rigorous trial design, including more specific patient selection criteria (ensure homogeneity of stroke location and severity), stratified randomization algorithms (time-to-treat), narrowed therapeutic time-window and pharmacokinetic monitoring. Current trials have also incorporated biologic surrogate markers of toxicity and outcome such as drug levels and neuroimaging. Lastly, multi-modal therapies and coupled cytoprotection/reperfusion strategies are being investigated to optimize tissue salvage. This review will focus on individual therapeutic strategies and we will emphasize what we have learned from these trials both in terms of trial design and the biologic effect (or lack thereof) of these agents.

View all citing articles on Scopus

View full text

Failure of the lipid peroxidation inhibitor U74006F to improve neurological outcome after transient forebrain ischemia in the rat

Abstract

Eur. J. Pharmacol.

Brain Research

Neurosci. Lett.

Effects of emopamil in postischemic blood flow and cell damage in the rat brain

Naunyn-Schmiedeberg's Arch. Pharmacol.

Attenuation of postischemic cerebral hypoperfusion by the 21-aminosteroid U74006F

Stroke

21-aminosteroid lipid peroxidation inhibitor U74006F protects against cerebral ischemia in gerbils

Stroke